Embolotherapy Market to Grow with a CAGR of 8.35% through 2030F
Rapid technological
advancement, increased prevalence of cancer and wide acceptance of embolization
procedures is expected to drive the Global Embolotherapy Market growth in the
forecast period, 2026-2030.
According to TechSci Research report, “Embolotherapy Market - Industry
Size, Share, Trends, Opportunity, and Forecast, 2020–2030F”, the Global
Embolotherapy Market stood at USD 3.67 billion in 2024 and is anticipated to
grow with a CAGR of 8.35% in the forecast period, 2026-2030. The embolotherapy
devices market has experienced steady growth over the past decade, fueled by
several key factors. These include a growing target patient population, rising
preference for minimally invasive procedures, increased government and private
sector investments, ongoing technological advancements in embolotherapy
devices, and supportive reimbursement policies for minimally invasive
treatments. Together, these drivers are propelling wider adoption and continued
innovation within the global embolotherapy landscape.
Cardiovascular disease
(CVD) remains a major health concern due to its high prevalence, especially
among individuals aged 80 and above, where rates exceed 20%. This drives
growing demand for embolotherapy procedures, valued for their high success
rates and low postoperative complications. Rising cases of liver cancer and
hepatocellular carcinoma also contribute to increased use of embolotherapy
devices. Liver cancer is the fifth most common cancer in men and ninth in
women, with over 840,000 new global cases in 2018 (World Cancer Research Fund).
The UK has seen a 42% rise in kidney cancer incidence over the past decade,
with rates increasing by 38% in men and 44% in women.
While emerging markets
and expanding clinical applications offer significant growth potential, the
market also faces challenges, including limited clinical evidence, regulatory
hurdles, and competition from alternative therapies. Nonetheless, continued preference
for minimally invasive treatments, rising incidence of vascular diseases, and
strong investment in R\&D support the market’s positive long-term outlook.
Browse over XX market data Figures spread through XX Pages and an in-depth
TOC on "Global Embolotherapy Market”
The global embolotherapy market is experiencing strong growth driven by
multiple factors. A rising patient population increasingly favors minimally
invasive procedures to treat conditions such as liver and kidney cancers,
hepatocellular carcinoma, renal cell carcinoma, aneurysms, and varicose veins.
Embolotherapy is widely used for non-trauma vascular disorders and
inflammation, further fueling demand. Additional growth drivers include
improved healthcare infrastructure, higher healthcare spending, and the rising
burden of target diseases. Government grants, private funding, favorable
reimbursement policies, and new product launches are also boosting market
momentum. The growing adoption of minimally invasive techniques across
neurological, vascular, and urological procedures, along with a consolidated
healthcare market and stronger purchasing power among providers, continues to
support market expansion. Together, these factors are shaping a robust outlook
for the global embolotherapy market.
The Global Embolotherapy Market is segmented into product, indication,
procedure, end user, regional distribution, and company.
Based on indications, the global embolotherapy market is segmented into
Oncology, Vascular, Aneurysm, Urology, and Nephrology. The oncology segment
held the largest revenue share in 2024 and is projected to register strong CAGR
growth over the forecast period. This is primarily driven by the rising global
incidence of liver and kidney cancers and the increasing use of chemoembolization
procedures in hospitals, particularly for liver cancer treatment.
Chemoembolization is often used when conventional treatments are unsuitable and
can be combined with chemotherapy, radiation, or liver ablation. The growing
prevalence of hepatocellular carcinoma has further boosted demand for
transarterial chemoembolization (TACE) as a palliative care option, supporting
continued revenue growth in the oncology segment.
Based on region, Asia-Pacific is the fastest-growing region in the global
embolotherapy market due to a combination of demographic, economic, and
healthcare-related factors. The region is experiencing a rapid rise in the
incidence of chronic diseases such as liver cancer, kidney cancer, and
cardiovascular conditions, which significantly increases the demand for
embolotherapy procedures. Countries like China, India, and Japan have large
aging populations, who are more susceptible to such conditions, further
expanding the target patient pool. The improving healthcare infrastructure,
growing access to advanced medical technologies, and increased healthcare
spending are supporting the market’s growth. Governments and private sectors
across the region are investing heavily in modernizing hospitals and expanding
interventional radiology capabilities. The increasing awareness of minimally
invasive treatment options and a shift toward value-based healthcare are
accelerating the adoption of embolotherapy. The presence of favorable
reimbursement policies in some countries, coupled with ongoing clinical research
and local manufacturing initiatives, also boosts regional market development.
Asia-Pacific presents a fertile ground for rapid expansion in the embolotherapy
market.
Major companies operating in Global Embolotherapy Market
are:
·
Medtronic, PLC
·
Microport Scientific
Corp.
·
Boston Scientific
Corporation
·
Stryker Corporation
·
Terumo Corporation
·
Penumbra, Inc.
·
Sirtex (CDH)
·
Johnson & Johnson
·
Abbott Laboratories Inc.
·
Balt Group (Balt
Extrusion SAS)
Download Free Sample Report
Customers can also
request for 10% free customization on this report.
“The global embolotherapy market is set for strong growth, driven by rising
cases of hepatic cancers, HCC, RCC, aneurysms, and varicose veins. Increasing
demand for minimally invasive procedures and higher mortality rates are key
contributors. Expanding healthcare infrastructure, greater R\&D
investments, and technological advancements further support market expansion.
The market offers diverse products like microspheres, coils, and plugs, with
chronic disease prevalence, especially cancer, continuing to fuel global demand
for embolotherapy solutions” said Mr. Karan Chechi, Research Director with
TechSci Research, a research-based management consulting firm.
“Embolotherapy Market
Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By
Product {Embolic Agents (Microspheres, Liquid Embolic Agents, Coil),
Microcatheters}, By Indication (Oncology, Vascular, Aneurysm, Urology,
Nephrology), By Procedure (TACE, TARE), By End User (Hospital, Clinics,
Ambulatory Surgery Centers), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global
Embolotherapy Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Embolotherapy
Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com